ClinicalTrials.gg
Not yet recruitingNCT07519070Updated Apr 9, 2026

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis

A Phase 3 interventional study of HSK44459 and HSK44459 in IPF, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Not yet recruiting. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

This study aims to evaluate the efficacy and safety of HSK44459 tablets in patients with idiopathic pulmonary fibrosis (IPF).

02

Conditions studied

  • IPF
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥40 years, regardless of gender;
  2. Diagnosis of IPF confirmed prior to or during screening per the 2022 ATS/ERS/JRS/ALAT guidelines (Appendix 1);
  3. Patients must meet one of the following criteria:

    1. No treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening (e.g., treatment-naïve or discontinued therapy), with no plans to initiate or resume antifibrotic treatment;
    2. On a stable regimen of nintedanib or pirfenidone for at least 12 weeks prior to screening, without combination therapy with both drugs. [Stable therapy is defined as maintaining a constant dosage with tolerable drug-specific adverse events];
  4. Percentage predicted forced vital capacity (FVCpp) ≥45% at screening;
  5. Percentage predicted diffusing capacity of the lungs for carbon monoxide (DLCOpp) ≥25% and \<90% at screening [* (Hb)-adjusted];
  6. Willing to participate and voluntarily sign the form.

Exclusion criteria

Exclusion Criteria:

  1. airway obstruction during screening [pre-bronchodilator /forced vital capacity (FEV1/FVC) \<0.7];
  2. Other clinically significant pulmonary abnormalities per investigator judgment (exceptions: conditions requiring no treatment during the trial, e.g., asymptomatic pulmonary nodules, emphysema);
  3. Acute IPF exacerbation within 3 months before screening and/or during screening;
  4. Receiving immunomodulators (excluding oral ) for respiratory conditions, or prednisone >15 mg/day (or equivalent);
  5. History of vasculitis;
  6. Any suicidal behavior within 2 years before screening (actual attempt, interrupted attempt, aborted attempt, or preparatory acts/behaviors);
  7. Type 4 or 5 suicidal ideation per Columbia-Suicide Severity Rating Scale (C-SSRS) within 3 months before/during screening (active suicidal thoughts with method/intent but no plan, or with method/intent/plan);
  8. Respiratory infection requiring antibiotics or other infections requiring treatment within 4 weeks before/during screening;
  9. Major surgery within 3 months before screening or planned during the study (investigator-assessed; lung transplant listing excluded);
  10. within 5 years before screening (except treated basal cell carcinoma, squamous cell carcinoma in situ, or cervical carcinoma in situ);
  11. Blood pressure ≥160/100 mmHg at screening;
  12. Unstable/worsening cardiovascular/cerebrovascular disease within 6 months before screening (e.g., unstable angina, myocardial infarction, heart failure, thromboembolic events including stroke/);
  13. (AST) or alanine transaminase (ALT) >2.5× or total >1.5×ULN at screening;
  14. Estimated (eGFR) ≤30 mL/min/1.73 m² at screening;
  15. Gastrointestinal surgery/disease affecting pharmacokinetics (PK) (except appendectomy/hernia repair);
  16. Active [HBsAg-positive with HBV-DNA above ULN], antibody-positive, syphilis (anti-TP-positive with TRUST above ULN), or infection (anti-HIV-positive) at screening;
  17. Current treated liver disease with A/B/C impairment at screening;
  18. Substance abuse, drug use, or excessive alcohol intake (>2 units/day; 1 unit=360 mL beer [5%], 45 mL spirits [40%], or 150 mL wine) within 3 months before screening;
  19. Tobacco/nicotine product use within 3 months before screening or unwillingness to abstain during the study;
  20. Previous HSK44459 use or PDE1/3/4/10/non-selective PDE inhibitor treatment (excluding HSK44459, e.g., apremilast, roflumilast, ibudilast) within 8 weeks before screening;
  21. Use of strong inhibitors/inducers within 14 days or 5 half-lives (whichever longer) before first dose, or anticipated need during the study;
  22. History of severe drug allergy or to product/;
  23. Participation in other clinical trials (receiving investigational drug/placebo) within 1 month before screening;
  24. Pregnancy/lactation; participants of unwilling to use during and for 3 months post-study (including male participants);
  25. Any other investigator-determined factors making participation unsuitable.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    HSK44459

    Drug: HSK44459

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • HSK44459 Without IPF background therapy

  • HSK44459 With Nintedanib

  • HSK44459 With Pirfenidone

  • DrugPlacebo

    Placebo Without IPF background therapy

  • DrugPlacebo

    Placebo With Nintedanib

  • DrugPlacebo

    Placebo With Pirfenidone

06

What researchers measure

Primary outcomes

  1. Change in FVC from baseline at Week 52

    Time frame: Week 52

Secondary outcomes

  1. Time to first acute IPF exacerbation during the trial

    Time frame: Week 52

  2. Time to first respiratory-related hospitalization during the trial

    Time frame: Week 52

  3. Time to >5% relative/absolute decline in FVC% predicted from baseline during the trial

    Time frame: Week 52

  4. Time to >10% relative/absolute decline in FVC% predicted from baseline during the trial

    Time frame: Week 52

  5. Time to >15% absolute decline in DLCO% predicted from baseline during the trial

    Time frame: Week 52

  6. Time to first antifibrotic (rescue) therapy use during the trial (non-antifibrotic arm only)

    Time frame: Week 52

  7. Time to death during the trial

    Time frame: Week 52

  8. Change from baseline in Living with Pulmonary Fibrosis (L-PF) questionnaire total score, impact score, and symptom total score at Week 52

    Time frame: Week 52

  9. Change from baseline in L-PF questionnaire symptom domain - dyspnea score at Week 52

    Time frame: Week 52

  10. Change from baseline in L-PF questionnaire symptom domain - cough score at Week 52

    Time frame: Week 52

  11. Change from baseline in L-PF questionnaire symptom domain - fatigue score at Week 52

    Time frame: Week 52

  12. Change from baseline in EQ-5D score at Week 52

    Time frame: Week 52

  13. Change from baseline in FVC at Week 26

    Time frame: Week 26

  14. Absolute change from baseline in FVC% predicted at Weeks 26 and 52

    Time frame: Weeks 26 and 52

  15. Absolute change from baseline in DLCO% predicted at Weeks 26 and 52

    Time frame: Weeks 26 and 52

  16. Change from baseline in resting SpO2 (expressed as percentage) at Week 52

    Time frame: Week 52

  17. Annualized rate of respiratory-related hospitalizations

    Time frame: Week 52

Other outcomes

  1. Time to first occurrence of any component of the composite endpoint during the trial: first FVC% predicted decline >10% from baseline, acute IPF exacerbation, first respiratory-related hospitalization, or death (whichever occurs first)

    Key secondary efficacy endpoint

    Time frame: Week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Apr 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 9, 2026
StartEst.
Apr 5, 2026
Primary completionEst.
Apr 5, 2028
CompletionEst.
Dec 30, 2028
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07519070
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Apr 5, 2026 (estimated)
Primary completion
Apr 5, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Apr 9, 2026

Study contacts

Zuojun Xu, PhD
Contact
xuzj@hotmail.com
+86-010-69156114

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK44459

Start the discussion